Brand Name
Zepatier
Generic Name
Elbasvir
View Brand Information FDA approval date: January 28, 2016
Classification: Hepatitis C Virus NS3/4A Protease Inhibitor
Form: Tablet
What is Zepatier (Elbasvir)?
ZEPATIER ® is indicated for the treatment of chronic hepatitis C virus genotype 1 or 4 infection in adults. ZEPATIER is indicated for use with ribavirin in certain patient populations [see Dosage and Administration.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment